10 principais enhertu.com concorrentes

trodelvy.com

Learn how TRODELVY® (sacituzumab govitecan‐hziy) is thought to work in adult patients with pretreated HR+/HER2- metastatic breast cancer. TRODELVY is an antibody‐drug. For adult patients. See Important Facts & Important Warning.

daiichisankyo.com

daiichi sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.

lorbrena.com

See risks and benefits. Learn more about how to help identify and manage potential side effects when taking LORBRENA® (lorlatinib).

keytruda.com

learn about keytruda® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. visit the patient website.

ibrance.com

See risks and benefits of IBRANCE® (palbociclib). Find information and treatment considerations for newly diagnosed HR+/HER2- Metastatic Breast Cancer (mBC).

xtandi.com

Watch patient testimonials to hear their experiences with XTANDI® (enzalutamide).

alunbrig.com

Please see Important Safety, Patient, and Prescribing Information.

phesgo.com

Learn about Liv and her experience receiving PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) for HER2-positive breast cancer. See Full Safety, including most serious side effects, for more information.

ontada.com

Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, was awarded a competitive contract with the U.S. Food and Drug Administration (FDA) to advance the use of real-world data (RWD) in the U.S. community oncology setting. The research aims to strengthen the scientific understanding of the natural history of rare cancers by leveraging Ontada’s community oncology footprint, unique RWD, and experience in real-world research (RWR).